Zobrazeno 1 - 10
of 22
pro vyhledávání: '"John Bothos"'
Autor:
Daniel P. Petrylak, Pablo Martinez, Song Cho, Kapil Vashisht, Meina Liang, Anton I. Rosenbaum, Marna Williams, Peng He, Qu Zhang, Mary Jane Hinrichs, John Bothos, Manuel Selvi Miralles, Richard Cathomas, Judy S. Wang, Mark T. Fleming, Johann S. de Bono
Per-patient ADA responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8ed549e5806b16ebd18f122d134b36f
https://doi.org/10.1158/1078-0432.22481330
https://doi.org/10.1158/1078-0432.22481330
Autor:
Daniel P. Petrylak, Pablo Martinez, Song Cho, Kapil Vashisht, Meina Liang, Anton I. Rosenbaum, Marna Williams, Peng He, Qu Zhang, Mary Jane Hinrichs, John Bothos, Manuel Selvi Miralles, Richard Cathomas, Judy S. Wang, Mark T. Fleming, Johann S. de Bono
Summary of mean (%CV) PK parameters of Total ADC and Active ADC after a single IV infusion of MEDI3726
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7724c99edd8d3a0ee5b1984cf8685d
https://doi.org/10.1158/1078-0432.22481336
https://doi.org/10.1158/1078-0432.22481336
Autor:
Daniel P. Petrylak, Pablo Martinez, Song Cho, Kapil Vashisht, Meina Liang, Anton I. Rosenbaum, Marna Williams, Peng He, Qu Zhang, Mary Jane Hinrichs, John Bothos, Manuel Selvi Miralles, Richard Cathomas, Judy S. Wang, Mark T. Fleming, Johann S. de Bono
CTC while on treatment (patients with at least one CTC measurement >50)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1327fb0781f338470585d55ccfdf376c
https://doi.org/10.1158/1078-0432.22481345.v1
https://doi.org/10.1158/1078-0432.22481345.v1
Autor:
Daniel P. Petrylak, Pablo Martinez, Song Cho, Kapil Vashisht, Meina Liang, Anton I. Rosenbaum, Marna Williams, Peng He, Qu Zhang, Mary Jane Hinrichs, John Bothos, Manuel Selvi Miralles, Richard Cathomas, Judy S. Wang, Mark T. Fleming, Johann S. de Bono
Mutation profiles in ctDNA: truncating and/or pathogenic mutations in DDR or DDR-related pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae47a30e84d5fba46594879d91fa09cd
https://doi.org/10.1158/1078-0432.22481342
https://doi.org/10.1158/1078-0432.22481342
Autor:
Rebecca A. Moss, Janice M. Mehnert, Blase Polite, Mark J. Ratain, Amy Peterson, Daniel V.T. Catenacci, Ihsan Nijem, Surinder Kaur, Shuang Bai, Priti Hegde, Steve Eppler, Wei Yu, John Bothos, Premal Patel, Ravi Salgia
PDF file - 88K, Table S1. Treatment-related adverse events across all dosing cohorts in Phase Ia escalation and expansion, and Phase Ib. Table S2. Most commonly reported adverse events regardless of relationship to study drug.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f7f6584b5adf11cb2797c9f5c4ef90
https://doi.org/10.1158/1078-0432.22451313
https://doi.org/10.1158/1078-0432.22451313
Autor:
Rebecca A. Moss, Janice M. Mehnert, Blase Polite, Mark J. Ratain, Amy Peterson, Daniel V.T. Catenacci, Ihsan Nijem, Surinder Kaur, Shuang Bai, Priti Hegde, Steve Eppler, Wei Yu, John Bothos, Premal Patel, Ravi Salgia
Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the receptor tyrosine kinase MET.Experimental Design: This 3+3 dose-escalation study compr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f7df0c5a4ee8a3a8ac96c8507697062
https://doi.org/10.1158/1078-0432.c.6522162.v1
https://doi.org/10.1158/1078-0432.c.6522162.v1
Autor:
Daniel P. Petrylak, Pablo Martinez, Song Cho, Kapil Vashisht, Meina Liang, Anton I. Rosenbaum, Marna Williams, Peng He, Qu Zhang, Mary Jane Hinrichs, John Bothos, Manuel Selvi Miralles, Richard Cathomas, Judy S. Wang, Mark T. Fleming, Johann S. de Bono
Purpose:MEDI3726 is an antibody–drug conjugate targeting the prostate-specific membrane antigen and carrying a pyrrolobenzodiazepine warhead. This phase I study evaluated MEDI3726 monotherapy in patients with metastatic castration-resistant prostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcb56fd85cee8a652c6debce500acf0
https://doi.org/10.1158/1078-0432.c.6530666.v1
https://doi.org/10.1158/1078-0432.c.6530666.v1
Autor:
Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Scientia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Scientia
PURPOSE Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0642b904bde8dff801a491fde48a500f
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6931
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6931
Autor:
Anna Brékine, Georgios Leventakis, Jart Armin, Anastasios Papathanasiou, Georgios Germanos, Sébastien Ziegler, Adrian Quesada Rodriguez, Georgios Kokkinis, Christopher Hemmens, Dimitrios Kavallieros, John Bothos
Publikováno v:
Internet of Things Security and Data Protection ISBN: 9783030049836
This chapter will share some key results from the SAINT project starting with an overview of the people who form the cybercrime network including attackers, victims and the organisations who are attempting to protect them. Then we will elaborate on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b580989de11accbb543afc5a3aff0b98
https://doi.org/10.1007/978-3-030-04984-3_5
https://doi.org/10.1007/978-3-030-04984-3_5
Autor:
Steven Sun, Mats Jerkeman, Simon Rule, Georg Hess, John Bothos, Isabelle Bence-Bruckler, Mathias Witzens-Harig, Nibedita Bandyopadhyay, Fritz Offner, Christopher Enny, Jessica Vermeulen, Dolores Caballero, Aleksandra Rizo, Shana Traina, Sriram Balasubramanian, Chiara Rusconi, Martin Dreyling, Cristina João, Seok-Goo Cho, Rodrigo Santucci Silva, Jenna D. Goldberg, Marek Trneny, Wojciech Jurczak
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f3968cb14298604d326493927a7acf
https://ruj.uj.edu.pl/xmlui/handle/item/117399
https://ruj.uj.edu.pl/xmlui/handle/item/117399